Literature DB >> 19829728

PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations.

Urban Emmenegger1, Yoo-Joung Ko.   

Abstract

Entities:  

Year:  2009        PMID： 19829728      PMCID： PMC2758513          DOI： 10.5489/cuaj.1146

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

1.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Authors:  Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Authors:  Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

3.  Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

Authors:  Andrew J Armstrong; Elizabeth Garrett-Mayer; Yi-Chun Ou Yang; Michael A Carducci; Ian Tannock; Ronald de Wit; Mario Eisenberger
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

4.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.

Authors:  Kenji Kuroda; He Liu; Sae Kim; Ming Guo; Vincent Navarro; Neil H Bander
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

7.  A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer.

Authors:  Mikael Hanninen; Peter Venner; Scott North
Journal:  Can Urol Assoc J       Date:  2009-10       Impact factor: 1.862

Review 8.  Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Authors:  Andrew J Armstrong; Phillip G Febbo
Journal:  Oncologist       Date:  2009-08-14

9.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

10.  A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

Authors:  K N Chi; S L Ellard; S J Hotte; P Czaykowski; M Moore; J D Ruether; A J Schell; S Taylor; C Hansen; I Gauthier; W Walsh; L Seymour
Journal:  Ann Oncol       Date:  2007-12-03       Impact factor: 32.976
  10 in total
  6 in total

1.  Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study.

Authors:  Manoj Gupta; Partha Sarathi Choudhury; Sudhir Rawal; Harish Chandra Goel; S Avinash Rao
Journal:  Nucl Med Mol Imaging       Date:  2018-09-26

2.  Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

Authors:  J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-30

3.  Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

Authors:  J G C van Hasselt; A Gupta; Z Hussein; J H Beijnen; J H M Schellens; A D R Huitema
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-30

4.  Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography.

Authors:  Manoj Gupta; Partha Sarathi Choudhury; Sudhir Rawal; Harish Chandra Goel; Shriram Avinash Rao
Journal:  Urol Ann       Date:  2019 Apr-Jun

5.  A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Authors:  M Wilbaux; M Tod; J De Bono; D Lorente; J Mateo; G Freyer; B You; E Hénin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-24

6.  Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.

Authors:  Erik M Velez; Bhushan Desai; Lingyun Ji; David I Quinn; Patrick M Colletti; Hossein Jadvar
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.